BACKGROUND AND PURPOSE:Combination radiofrequency ablation and vertebral augmentation is an emerging minimally invasive therapy for patients with metastatic spine disease who have not responded to or have contraindications to radiation therapy. The purpose of this study was to evaluate the rate of radiographic local control of spinal metastases treated with combination radiofrequency ablation and vertebral augmentation.

No abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has induced a tremendous toll on our health care system and society, but the rapid development of effective vaccines using novel mRNA technology in less than 1 year represents an unprecedented scientific achievement. In December 2020, the Pfizer-BioNTech (New York, NY, USA and Mainz, Germany) (BNT162b2) and Moderna (Cambridge, MA, USA) (mRNA-1273) vaccines were approved by the US Food and Drug Administration under an Emergency Use Authorization based on phase 2/3 clinical trial data showing high efficacy in preventing symptomatic SARS-CoV-2 infection with a favorable safety profile in more than 70,000 individuals, but recipients of immunosuppressive medications, including liver transplantation (LT) recipients, were excluded from the trials. (1,2) In this setting of rapid deployment, little is known of the efficacy and potential risks of novel SARS-CoV-2 vaccination in LT recipients. We report an episode of steroid-resistant acute cellular rejection (ACR) in an LT recipient occurring after the first dose of the Moderna vaccine.

Patients born with complex congenital heart disease are hospitalized far more frequently than the general US population, primarily for cardiac-related illness. Future research should focus on confirming the present findings and on identification of strategies to improve outcomes in this growing group of patients.

Although liver transplantation (LT) yields survival benefit for patients with acute-on-chronic liver failure grade 3 (ACLF-3), knowledge gaps remain regarding risk factors for post-LT mortality. We retrospectively reviewed data from 10 centers in the United States and Canada for patients transplanted between 2018 and 2019 and who required care in the intensive care unit prior to LT. ACLF was identified using the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) criteria. A total of 318 patients were studied, of whom 106 (33.3%) had no ACLF, 61 (19.1%) had ACLF-1, 74 (23.2%) had ACLF-2, and 77 (24.2%) had ACLF-3 at transplantation. Survival probability 1 year after LT was significantly higher in patients without ACLF (94.3%) compared with patients with ACLF (87.3%; P = 0.02), but similar between ACLF-1 (88.5%), ACLF-2 (87.8%), and ACLF-3 (85.7%; P = 0.26). Recipients with ACLF-3 and circulatory failure (n = 29) had similar 1-year post-LT survival (82.3%) compared with patients with ACLF-3 without circulatory failure (89.6%; P = 0.32), including those requiring multiple vasopressors. For patients transplanted with ACLF-3 including respiratory failure (n = 20), there was a trend toward significantly lower post-LT survival (P = 0.07) among those with respiratory failure (74.1%) compared with those without (91.0%). The presence of portal vein thrombosis (PVT) at LT for patients with ACLF-3 (n = 15), however, yielded significantly lower survival (91.9% versus 57.1%; P < 0.001). Multivariable logistic regression analysis revealed that PVT was significantly associated with post-LT mortality within 1 year (odds ratio, 7.3; 95% confidence interval, 1.9-28.3). No correlation was found between survival after LT and the location or extent of PVT, presence of transjugular intrahepatic portosystemic shunt, or anticoagulation. LT in patients with ACLF-3 requiring vasopressors yields excellent 1-year survival. LT should be approached cautiously among candidates with ACLF-3 and PVT.